Quest Diagnostics (DGX) Tops Q1 EPS by 13c, Beats on Revenue; Offers FY26 Guidance

Quest Diagnostics (NYSE: DGX) reported Q1 EPS of $2.50, $0.13 better than the analyst estimate of $2.37. Revenue for the quarter came in at $2.9 billion versus the consensus estimate of $2.83 billion.

GUIDANCE:

Quest Diagnostics sees FY2026 EPS of $10.63-$10.83, versus the consensus of $10.63. Quest Diagnostics sees FY2026 revenue of $11.78-11.9 billion, versus the consensus of $11.76 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• CMS targets 15% Medicare lab fee cuts, putting DGX and LH revenue at risk
• GameStop shares rise as CEO Cohen buys $26.4M in stock
• Sun Life to consolidate preferred shares Series 11QR into Series 10R